Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance-Reference-Cited by-同舟云学术

Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance

Published:2021-08 Issue: Volume:202 Page:114147
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Li Na,Mao Weimin,Gao Yun,Wang Ding,Song Zhengbo,Chen Zhongjian

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference35 articles.

1. Integrative omics analysis reveals soluble Cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer;Hsiao;Clin. Cancer Res.,2020

2. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers;Chapman;Lung Cancer.,2016

3. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer;Tong;Respir. Res.,2019

4. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer;Yochum;Oncogene.,2019

5. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors;Westover;Ann. Oncol.,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accurate and rapid molecular subgrouping of high-grade glioma via deep learning-assisted label-free fiber-optic Raman spectroscopy;PNAS Nexus;2024-05-27

2. Cytosolic malic enzyme and glucose‐6‐phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance;The FEBS Journal;2023-07-13

3. Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance;Biomedicines;2022-01-26